Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet study)

Peritoneal Dialysis International

Volumn 28, Issue SUPP. 3, 2008, Pages

  Kim, Sung Gyun ^a   Kim, Sejoong ^b   Hwang, Young Hwan ^c   Kim, Kiwon ^d   Oh, Ji Eun ^a   Chung, Wookyung ^e   Oh, Kook Hwan ^b   Kim, Hyung Jik ^a   Ahn, Curie ^b  

^a Hallym University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Eulji University   (South Korea)

^d National Cancer Center   (South Korea)

^e Gacheon University of Medicine and Science   (South Korea)

Author keywords

Biocompatability; Glucose degradation products; Residual renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; PERITONEAL DIALYSIS FLUID;

ACID BASE BALANCE; ADULT; ANION GAP; BIOCOMPATIBILITY; CARBON DIOXIDE BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ACID-BASE EQUILIBRIUM; DIALYSIS SOLUTIONS; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES;

EID: 48749085982     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59:348-57.
2. Van Biesen W, Dequidt C, Vijt D, Vanholder R, Lameire N. Analysis of the reasons for transfers between hemodialysis and peritoneal dialysis and their effect on survivals. Adv Perit Dial 1998; 14:90-4.
3. Williams JD, Craig KJ, von Ruhland C, Topley N, Williams GT. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003; 88:S43-9.
4. Topley N. Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. Adv Ren Replace Ther 1998; 5:179-84.
5. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000; 20(Suppl 4):S22-42.
6. Millar DJ, Holmes C, Faict D, Dawnay A. Comparison of in vitro age formation between standard PD fluid and a novel bicarbonate/lactate formulation. Adv Perit Dial 1998; 14:191-4.
7. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11:729-39.
8. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54:2424-9.
9. Wieczorowska-Tobis K, Brelinska R, Witowski J, Passlick-Deetjen J, Schaub TP, Schilling H, et al. Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 2004; 24:48-57.
10. Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jörres A, Lage C, et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004; 19:917-24.
11. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. on behalf of the Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
12. Davies SJ, Russell L, Bryan J, Phillips L, Russell GI. Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 1995; 26:353-61.
13. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552-9.
14. Konings CJ, Kooman JP, Gladziwa U, van der Sande FM, Leunissen KM. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67:1190-1.
15. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63:1556-63.
16. Feriani M, Kirchgessner J, LaGreca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54:1731-8.